Tedizolid [CAS 856866-72-3]

Tedizolid [CAS 856866-72-3]

Catalog Number:
CR04341318TOK
Mfr. No.:
TOK-T117
Price:
$392
  • Size:
    Quantity:
    Add to Cart:
    Add to Cart
      • Overview

        • Tedizolid is an oxazolidone antibiotic. It is an oxazolidinone, but differs from other oxazolidinones by having a modified side chain at the C-5 position of the oxazolidinone nucleus which confers activity against certain linezolid-resistant pathogens. It also has an optimized C- and D-ring system that improves its potency via addiitonal binding site interactions. The compound was formerly known as Torezolid. Tedizolid is bacteriostatic against Gram-positive organisms. As with linezolid, Tedizolid is a weak, reversible MAO inhibitor.
          Tedizolid is slightly soluble in ethanol, DMSO, and DMF.

          Please contact us at for specific academic pricing.

          Background

          Tedizolid binds to the 23S rRNA of the 50S ribosomal subunit, preventing the formation of the 70S initiation complex and inhibiting protein synthesis.

      • Properties
        • CAS Number
          856866-72-3
          Molecular Formula
          C17H15FN6O3
          Molecular Weight
          370.34
          Appearance
          White to off-white powder
          Solubility
          Slightly soluble in ethanol, DMSO and DMF
          Other Properties
          Source: Synthetic
          Purity Level: ≥99.0% (by HPLC)
          Storage
          2-8 °C

          * For research use only

      • Applications
        • Application Description
          Spectrum: Tedizolid has activity against Gram-positive bacteria including MRSA and VRE, and linezolid-resistant strains with the cfr gene, in the absence of certain ribosomal mutations conferring reduced oxazolidinone susceptiibility. It has enhanced in vitro activity against Gram-positive aerobic bacteria. It also has activity against several Mycobacterium spp, including Mycobacterium tuberculosis and nontuberculous mycobacterium.

          Microbiology Applications: Tedizolid is four- to eightfold more potent in vivo compared to linezolid against staphylocci, enterococci, and streptococci, incuding MRSA and vancomycin-resistant enterococci (VRE) and linezolid-resistant phenotypes. Tedizolid resistance is most commonly caused by mutations of the peptidyl transferase center (PTC) binding site on the 50S subunit of the bacterial ribosome.
    MSDS

    Documents

    MSDS-EU

    We Also Recommend

    Tedizolid Phosphate

    Tedizolid Phosphate

    $290